What is the effect of an antibody directed against IL-5 (Mepolizumab) in the inflammatory reaction in asthmatic patients

Dual homing mechanisms of eosinophils to the sputum; only one of which is sensitive for mepolizumab

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26875

Enrollment

Registered

2017-03-31

Start date

2017-02-14

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eosinophilic asthma, action of mepolizumab on lung inflammation.

Interventions

Mepolizumab

Eligibility

Inclusion criteria

Inclusion criteria: Age>18 and younger than 70 years Diagnosis of eosinophil asthma despite use of corticosteroids suitable for sputum induction >2.5 % sputum eosinophils

Exclusion criteria

Exclusion criteria: Any infection (e.g. HIV, hepatitis, STD's) Insulin dependent diabetes Smoking at present or in the last 12 months and/or a past history of more than 10 pack years Proven allergic bronchopulmonary aspergillosis

Design outcomes

Primary

Measure	Time frame
change in kinetics of eosinophils in the sputum	—

Secondary

Measure	Time frame
change in kinetics of eosinophils in the sputum change in systemic cytokines change in sputum markers for presence of eosinohils	—

Contacts

Public ContactL. Koenderman

Universitair Medisch Centrum Utrecht Secreteriaat Longziekten PO Box 85500

+31 (0)88 7557552

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)